# A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

> **NCT02963350** · — · APPROVED_FOR_MARKETING · sponsor: **BioMarin Pharmaceutical**

## Conditions studied

- CLN2 Disease

## Interventions

- **DRUG:** BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)

## Key facts

- **NCT ID:** NCT02963350
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02963350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02963350, "A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02963350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*